Abstract #3370
Radiomics for noninvasive prediction of HCC immunophenotyping
Enamul Bhuiyan1,2, Octavia Bane1,2, Paul Kennedy1,2, Sema Yildiz2, Muhammed Shareef2, M. Isabel Fiel3, Stephen Ward3, Myron Schwartz4, Thomas Marron5, Miriam Merad6, and Bachir Taouli1,2
1BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 4Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 5The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Synopsis
The reported rate of intrahepatic recurrence of hepatocellular carcinoma (HCC) after resection is high (up to 50%), even with negative surgical margins, which is postulated to be due to micrometastases. Immunotherapy present new possibilities in cancer treatment with encouraging results in HCC. Selection of patients for immunotherapy may be based on background immune features, thus imaging features associated with immunophenotype may aid in patient selection. Specifically, radiomics features exhibited a fair to excellent diagnostic performance for differentiating tumors with high vs. low/moderate tumor infiltrating lymphocytes (TILs) and presence vs absence of tertiary lymphoid structure (TLS) with AUC range of 0.70-0.95.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
